2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle  
09/11/17Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive agreements to sell securities to certain accredited investors in a private placement priced at-the-market, for aggregate gross proceeds of approximately $3.7 million. The closing of the private placement is expected to occur on or about September 13, 2017, subject to sat... 
 Printer Friendly Version
09/05/17Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard W. Pascoe, Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017, at 11:40 a.m. Eastern Time.  The conference will be held at The Lotte New York Palace Hotel in New York, NY.  Mr. Pascoe will provide an update ... 
 Printer Friendly Version
08/31/17Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission
PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has acknowledged receipt of its recently resubmitted New Drug Application (“NDA”) for Vitaros™ (alprostadil, DDAIP.HCl) and considers it a complete, class 2 response to Apricus’ 2008 action letter.  The PDUFA (Prescript... 
 Printer Friendly Version
08/29/17Apricus Biosciences Files NDA Resubmission for Vitaros™
Approval Decision Expected in First Quarter 2018 SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that it recently filed its resubmission of a New Drug Application (“NDA”) for Vitaros™ (alprostadil, DDAIP.HCl) with the U.S. Food and Drug Administration (“FDA”).  Apricus anticipates a six-month review by the FDA with a projected PDUFA (Prescription Drug Us... 
 Printer Friendly Version
08/02/17Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
Vitaros Drug-Device Human Factor Studies Successfully Completed Vitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current Quarter Conference Call / Webcast Today, August 2, 2017 at 4:30 p.m. ET SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2017 and provided a corporate update on its pr... 
 Printer Friendly Version
07/26/17Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ second quarter 2017 financial results will be released on Wednesday, August 2, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Wednesday, August 2, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. To pa... 
 Printer Friendly Version
05/11/17Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017 Vitaros Drug-Device Human Factor Studies Underway Operations Funded Through the Third Quarter of 2018 Conference Call / Webcast Today, May 11, 2017 at 4:30 p.m. ET SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2017 and provided a corporat... 
 Printer Friendly Version
05/04/17Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the Vitaros drug-device combination human factor testing study required by the Food and Drug Administration (FDA) is underway. “In November of 2016, the FDA designated Vitaros as a drug-device combination and required Apricus to provide a... 
 Printer Friendly Version
05/04/17Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ first quarter 2017 financial results will be released on Thursday, May 11, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Thursday, May 11, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. To participa... 
 Printer Friendly Version
05/02/17Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on May 2, 2017, Apricus was notified by The NASDAQ Stock Market LLC (“Nasdaq”) that Apricus has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders’ equity requirement. Nasdaq’s determination follows Apricus’ previously an... 
 Printer Friendly Version
04/21/17Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
SAN DIEGO, April 21, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the pricing of an underwritten public offering of an aggregate of 5,030,000 units, with each unit consisting of one share of Apricus common stock and one warrant to purchase 0.75 of a share of common stock, at a public offering price of $1.40 per unit.  The shares of common stock and warrants are immediate... 
 Printer Friendly Version
03/13/17Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today, Monday, March 13, 2017 at 4:30 p.m. ET SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and full year of 2016 and p... 
 Printer Friendly Version
03/09/17Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial results will be released on Monday, March 13, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Monday, March 13, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highl... 
 Printer Friendly Version
03/08/17Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-Closing SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it completed the sale to Ferring International Center S.A. (“Ferring”) of Apricus’ ex-U.S. assets and rights related to Vitaros®, Apricus’ on-deman... 
 Printer Friendly Version
02/09/17Apricus Biosciences Receives Positive Nasdaq Listing Determination
SAN DIEGO, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on February 8, 2017, the Company was notified that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on Nasdaq pursuant to an extension through May 30, 2017, by which date the Company must evidence full compliance with all applicable criteria for continued ... 
 Printer Friendly Version
02/08/17Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 9:00 a.m. Eastern Time.  The conference will be held at The Waldorf Astoria, New York, NY.  Mr. Pascoe will provide an update on Vitaros®, the Company's topical t... 
 Printer Friendly Version
01/18/17Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
Ferring Plans to Launch in Mexico and Argentina During the Second Quarter 2017 SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction. This is the twen... 
 Printer Friendly Version
01/03/17Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Mary Naggs has been promoted to Vice President, General Counsel, effective January 1, 2017.  Ms. Naggs will report directly to Richard Pascoe, the Company’s Chief Executive Officer, and serve as a member of the Company’s executive team. Ms. Naggs advances from the position of Associate General Couns... 
 Printer Friendly Version